Chrome Extension
WeChat Mini Program
Use on ChatGLM

Mitral Valve Disease: if the Mitral Valve is Not Reparable/failed Repair, is Bioprosthesis Suitable for Replacement?

European Journal of Cardio-thoracic Surgery(2009)SCI 2区SCI 3区

St Pauls Hosp | Univ British Columbia

Cited 23|Views18
Abstract
Objective: The durability of mitral bioprostheses has tong been known to be inferior to aortic bioprostheses. Mitral valve reconstruction/repair is currently recommended for most mitral valve procedures. The choice of prostheses for non-reparable or failed mitral valve repairs has not been specified or given appropriate attention within the literature. The objective of this study is to address the role of bioprostheses in the specific subset of non-reparable or failed repair patients by using the knowledge of the general durability of mitral porcine bioprostheses, inclusive of the Carpentier-Edwards mitral porcine bioprosthesis. Methods: The CE-SAV was implanted in 1135 patients (1175 operations) for mitral valve replacement (MVR) from 1982 to 2000. The mean age was 65.0 +/- 12.1 years (range 13-86 years). The mean follow-up was 6.4 +/- 4.5 years, 7555.9 patient-years and 98.3% complete. The evaluation considered freedom from structural valve deterioration (SVD) and freedom from composites of complications, as well as risk assessment. Results: For the 51-60 year age group, the actual and actuarial freedom from SVD was, at 18 years, 56.0 +/- 4.1% and 14.7 +/- 5.8%; for the 61-70 year age group was, at 18 years, 69.6 +/- 2.6% and 26.5 +/- 5.9%, respectively. For the >70 group, at 15 years was 92.2 +/- 2.0% and 69.0 +/- 9.7%, respectively. There were a total of 256 SVD events with 31 fatalities and 226 reoperations with 10 fatalities (4.42%). The predictors of SVD were age (hazard ratio [HR] 0.98, p = 0.0002), concomitant CAB (HR 0.66, p = 0.020) and valve size (HR 1.08, p = 0.034). The overall actual freedom, at 15-18 years, for >70 age group was, for valve-related reoperation, 94.3 +/- 1.5%; and for valve-related mortality was 87.8 +/- 2.3%. Conclusions: The CE-SAV mitral porcine bioprosthesis cannot be recommended as representative of prosthesis-type of choice for non-reparable or failed repair of native mitral valves for ages <= 70 years. The CE-SAV mitral porcine bioprosthesis is satisfactory for implantation >70 years of age. The clinical performance of the CE-SAV is similar to other mitral bioprostheses. (C) 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
More
Translated text
Key words
Valve disease,Mitral valve
PDF
Bibtex
AI Read Science
AI Summary
AI Summary is the key point extracted automatically understanding the full text of the paper, including the background, methods, results, conclusions, icons and other key content, so that you can get the outline of the paper at a glance.
Example
Background
Key content
Introduction
Methods
Results
Related work
Fund
Key content
  • Pretraining has recently greatly promoted the development of natural language processing (NLP)
  • We show that M6 outperforms the baselines in multimodal downstream tasks, and the large M6 with 10 parameters can reach a better performance
  • We propose a method called M6 that is able to process information of multiple modalities and perform both single-modal and cross-modal understanding and generation
  • The model is scaled to large model with 10 billion parameters with sophisticated deployment, and the 10 -parameter M6-large is the largest pretrained model in Chinese
  • Experimental results show that our proposed M6 outperforms the baseline in a number of downstream tasks concerning both single modality and multiple modalities We will continue the pretraining of extremely large models by increasing data to explore the limit of its performance
Try using models to generate summary,it takes about 60s
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Related Papers
AF Carpentier, Yau,LI Bonchek
2000

被引用167 | 浏览

Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn
Chat Paper

要点】:研究探讨了Carpentier-Edwards猪生物瓣(CE-SAV)在不可修复或修复失败的二尖瓣疾病患者中的适用性,发现其对于70岁以下患者不推荐使用,而对70岁以上患者则是满意的选择。

方法】:通过回顾性分析1982至2000年间接受CE-SAV植入的1135名患者的数据,评估了瓣膜的结构性退化情况、并发症组合以及风险评估。

实验】:实验使用了1982至2000年间进行二尖瓣置换手术(MVR)的1135名患者(共1175次手术)的数据,平均随访6.4年,涉及7555.9患者年,98.3%的数据完整性。结果显示,不同年龄段的患者在18年随访期内瓣膜的结构性退化率存在差异,70岁以上患者的实际和预期无结构性退化率较高,整体临床表现与其他二尖瓣生物瓣相似。